Receptor-OncoTek (Dr. C. Allen - University of Toronto)

Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Preclinical development of PoLi-PTX, Intraperitoneal ovarian cancer therapy

Related news

There are currently no news items related to this portfolio company.

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.